National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials (PDQ®)
Patient Version   Health Professional Version
Page Options
Print This Page
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Maintenance Rituximab for Follicular Lymphoma

Azacitidine Improves Survival in MDS

Second Stem Cell Transplant Not Helpful in Myeloma
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Basic Trial Information
Trial Description
     Summary
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overPharmaceutical / IndustryA4021018
NCT00673049

Trial Description

Summary

The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).

Eligibility Criteria

Inclusion Criteria:

  • Non small cell lung cancer with a primary histology of squamous cell, large cell or adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.

Exclusion Criteria:

  • Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.
  • Prior Erlotinib therapy.
  • Prior anti IGF IR based investigational therapy.

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call CenterStudy Director

Pfizer Oncology Clinical Trial Information ServicePh: 1-877-369-9753
  Email: PfizerCancerTrials@emergingmed.com

Pfizer CT.gov Call CenterPh: 1-800-718-1021

Trial Sites

U.S.A.
Arkansas
  Fort Smith
 Pfizer Investigational Site
  Hot Springs
 Pfizer Investigational Site
California
  Thousand Oaks
 Pfizer Investigational Site
Colorado
  Denver
 Pfizer Investigational Site
  Fort Collins
 Pfizer Investigational Site
  Lafayette
 Pfizer Investigational Site
Florida
  Hollywood
 Pfizer Investigational Site
  Lynn Haven
 Pfizer Investigational Site
  Pembroke Pines
 Pfizer Investigational Site
  The Villages
 Pfizer Investigational Site
Georgia
  Duluth
 Pfizer Investigational Site
  Lawrenceville
 Pfizer Investigational Site
  Snellville
 Pfizer Investigational Site
Indiana
  Avon
 Pfizer Investigational Site
  Beech Grove
 Pfizer Investigational Site
  Hobart
 Pfizer Investigational Site
  Indianapolis
 Pfizer Investigational Site
  Mooresville
 Pfizer Investigational Site
  Munster
 Pfizer Investigational Site
Iowa
  Waterloo
 Pfizer Investigational Site
Kentucky
  Louisville
 Pfizer Investigational Site
Maryland
  Baltimore
 Pfizer Investigational Site
  Bethesda
 Pfizer Investigational Site
  Clinton
 Pfizer Investigational Site
  Greenbelt
 Pfizer Investigational Site
Montana
  Billings
 Pfizer Investigational Site
  Butte
 Pfizer Investigational Site
Nebraska
  Omaha
 Pfizer Investigational Site
New Hampshire
  Lebanon
 Pfizer Investigational Site
New York
  Amherst
 Pfizer Investigational Site
  Buffalo
 Pfizer Investigational Site
  Lake Success
 Pfizer Investigational Site
  Manhasset
 Pfizer Investigational Site
  New Hyde Park
 Pfizer Investigational Site
Ohio
  Columbus
 Pfizer Investigational Site
Oklahoma
  Norman
 Pfizer Investigational Site
  Oklahoma City
 Pfizer Investigational Site
  Tulsa
 Pfizer Investigational Site
Texas
  Grapevine
 Pfizer Investigational Site
  Irving
 Pfizer Investigational Site
  San Antonio
 Pfizer Investigational Site
Vermont
  Bennington
 Pfizer Investigational Site
Washington
  Wenatchee
 Pfizer Investigational Site
Wyoming
  Cody
 Pfizer Investigational Site
Canada
  Quebec
 Pfizer Investigational Site
Chile
  Independencia
 Pfizer Investigational Site
France
  La Tronche
 Pfizer Investigational Site
  Lille
 Pfizer Investigational Site
  Marseille Cedex 09
 Pfizer Investigational Site
  Villejuif
 Pfizer Investigational Site
Indonesia
  Jakarta
 Pfizer Investigational Site
  Surabaya
 Pfizer Investigational Site
Italy
  Cattolica (RN)
 Pfizer Investigational Site
  Orbassano (Torino)
 Pfizer Investigational Site
  Rimini
 Pfizer Investigational Site
Latvia
  Riga
 Pfizer Investigational Site
Poland
  Gdansk
 Pfizer Investigational Site
  Krakow
 Pfizer Investigational Site
  Lublin
 Pfizer Investigational Site
  Olsztyn
 Pfizer Investigational Site
Puerto Rico
  Ponce
 Pfizer Investigational Site
Republic of Bulgaria
  Sofia
 Pfizer Investigational Site
  SOFIA
 Pfizer Investigational Site
  Varna
 Pfizer Investigational Site
Republic of Korea
  Seoul
 Pfizer Investigational Site
Russia
  Moscow
 Pfizer Investigational Site
  Sochi
 Pfizer Investigational Site
Serbia
  Belgrade
 Pfizer Investigational Site
Slovenia
  Ljubljana
 Pfizer Investigational Site
Spain
  BARCELONA
 Pfizer Investigational Site
  ELCHE
 Pfizer Investigational Site
  GIRONA
 Pfizer Investigational Site
  MADRID
 Pfizer Investigational Site
  MANRESA
 Pfizer Investigational Site
  SEVILLA
 Pfizer Investigational Site
Switzerland
  Basel
 Pfizer Investigational Site
  CH-4101 Bruderholz
 Pfizer Investigational Site
  Chur
 Pfizer Investigational Site
  Liestal
 Pfizer Investigational Site
Taiwan, Province of China
  Taichung
 Pfizer Investigational Site
  Taipei
 Pfizer Investigational Site
  Taoyuang
 Pfizer Investigational Site
Ukraine
  Dnipropetrovsk
 Pfizer Investigational Site
  Donetsk
 Pfizer Investigational Site
  Kharkiv
 Pfizer Investigational Site
  Kyiv
 Pfizer Investigational Site
  Sumy
 Pfizer Investigational Site
United Kingdom
  London
 Pfizer Investigational Site
  Manchester
 Pfizer Investigational Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00673049
Information obtained from ClinicalTrials.gov on March 05, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov